CONDITIONS OF URATE NEPHROLITHIASIS AND APPROACHES TO ITS MODELING
https://doi.org/10.24884/1561-6274-2017-21-4-48-54
Abstract
The review describes the pathophysiological factors that contribute to the development of uric acid nephrolithiasis. Different approaches to its modeling are presented. Noted the most favorable methods from the standpoint of modern concepts of the disease pathogenesis.
About the Authors
V. Yu. Perfilev
Department pharmacology, Altai State Medical University
Russian Federation
Russian Federation
Ya. F. Zverev
Department pharmacology, Altai State Medical University
Russian Federation
Prof., DMedSci.
Russian Federation
Prof., DMedSci.
A. Yu. Zharikov
Department pharmacology, Altai State Medical University
Russian Federation
Prof., DBiolSci.
Russian Federation
Prof., DBiolSci.
References
1. Bobulescu IA, Moe OW. Renal transport of uric acid: evolving concepts and uncertainties. Advances in chronic kidney disease 2012; 19 (6): 358-371
2. Wu X et al. Two independent mutational events in the loss of urate oxidase during hominoid evolution. Journal of molecular evolution 1992; 34 (1): 78-84
3. Alvarez-Lario B, Macarrón-Vicente J. Uric acid and evolution. Rheumatology 2010; 49 (11): 2010-2015
4. Doherty M. New insights into the epidemiology of gout. Rheumatology 2009; 48: ii2-ii8
5. Пытель ЮА, Золотарев ИИ. Уратный нефролитиаз. Медицина, М., 1995; 176 c [Pytel’ YUA, Zolotarev II. Uratnyj nefrolitiaz. M.: Medicina, 1995; 176 s]
6. Burns CM, Wortmann RL. Disorders of purine and pyrimidine metabolism. In: Faci AS, Longo DL, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, eds. Principles of Internal Medicine, McGraw-Hill, New York, 2012: 215-219
7. Kratzer JT, Lanaspa MA, Murphy MN et al. Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci USA 2014; 111 (10): 3763-3768
8. Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis The Lancet Neurology 2015; 14 (2): 183-193
9. Preitner F et al. Urate-induced acute renal failure and chronic inflammation in liver-specific Glut9 knockout mice American Journal of Physiology-Renal Physiology 2013; 305 (5): F786-F795
10. Зверев ЯФ, Брюханов ВМ. Современный взгляд на механизмы развития уратного нефролитиаза. Клин нефролог 2015; (5-6): 39-47 [Zverev YaF, Bryuhanov VM. Sovremennyj vzglyad na mekhanizmy razvitiya uratnogo nefrolitiaza. Klin nefrolog 2015; (5-6): 39-47]
11. Брюханов ВМ, Зверев ЯФ, Лампатов ВВ. и др. Влияние питьевых режимов на движущие силы кристаллизации при экспериментальном нефролитиазе. Урология 2011; 1: 6-11 [Bryuhanov VM, Zverev YAF, Lampatov VV i dr. Vliyanie pit’evyh rezhimov na dvizhushchie sily kristallizacii pri ehksperimental’nom nefrolitiaze. Urologiya 2011; 1: 6-11]
12. Зверев ЯФ, Брюханов ВМ, Лампатов ВВ, Жариков АЮ. Современные представления о роли физико-химических факторов в патогенезе кальциевого нефролитиаза. Нефрология 2009; 13 (1): 39-50 [Zverev YAF, Bryuhanov VM, Lampatov VV, ZHarikov AYU. Sovremennye predstavleniya o roli fiziko-himicheskih faktorov v patogeneze kal’cievogo nefrolitiaza. Nefrologiya 2009; 13 (1): 39-50]
13. Atan L et al. High kidney stone risk in men working in steel industry at hot temperatures. Urology 2005; 65 (5): 858-861
14. Robertson WG. Renal stones in the tropics. Seminars in nephrology 2003; 23 (1): 77-87
15. Yu TF, Gutman A.B. Uric acid nephrolithiasis in gout. Annals of internal medicine 1967; 67 (6): 1133-1148
16. Барскова ВГ, Мукагова МВ. Современные представления о патогенезе и методах коррекции уратного нефролитиаза у больных подагрой. Современная ревматология 2011; 4: 39-43 [Barskova VG, Mukagova MV. Sovremennye predstavleniya o patogeneze i metodah korrekcii uratnogo nefrolitiaza u bol’nyh podagroj. Sovremennaya revmatologiya 2011; 4: 39-43]
17. Alvarez-Nemegyei J et al. Prevalence and risk factors for urolithiasis in primary gout: is a reappraisal needed? The Journal of rheumatology 2005; 32 (11): 2189-2191
18. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. American Journal of Kidney Diseases 2002; 40 (1): 37-42
19. Kramer HJ et al. The association between gout and nephrolithiasis in men: The Health Professionals’ Follow-Up Study. Kidney international 2003; 64 (3): 1022-1026
20. Davidson MB et al. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. The American journal of medicine 2004; 116 (8): 546-554
21. Liebman SE, Taylor JG, Bushinsky DA. Uric acid nephrolithiasis. Current rheumatology reports 2007; 9 (3) 251-257
22. Руденская ГЕ, Захарова ЕЮ, Бессонова ЛА и др. Синдром Леша-Найхана: фенотипическое разнообразие и ДНК-диагностика. Медицинская генетика 2010; 9 (9): 41-48 [Rudenskaya GE, Zaharova EYU, Bessonova LA i dr. Sindrom Lesha-Najhana: fenotipicheskoe raznoobrazie i DNK-diagnostika. Medicinskaya genetika 2010; 9 (9): 41-48]
23. Ngo TC, Assimos DG. Uric acid nephrolithiasis: recent progress and future directions. Reviews in urology 2007; 9 (1): 17
24. Talente GM et al. Glycogen storage disease in adults. Annals of internal medicine 1994; 120 (3): 218-226
25. Wilson JM, Young AB, Kelley WN. Hypoxanthine-guanine phosphoribosyltransferase deficiency: the molecular basis of the clinical syndromes. New England Journal of Medicine 1983; 309 (15): 900-910
26. Tsimberidou A, Keating MJ. Hyperuricemic syndromes in cancer patients Hyperuricemic Syndromes: Pathophysiology and Therapy. Karger Publishers, 2004; 147: 47-60
27. Burckhardt G. Drug transport by organic anion transporters (OATs). Pharmacology & therapeutics 2012; 136 (1): 106-130
28. Mullin JW. Nucleation. In: Crystallization. ButterworthHeinemann, Oxford. 1993; 172-201
29. Anzai N et al. Recent advances in renal urate transport: characterization of candidate transporters indicated by genomewide association studies. Clinical and experimental nephrology 2012; 16 (1): 89-95
30. Lipkowitz MS. Regulation of uric acid excretion by the kidney. Current rheumatology reports 2012; 14 (2): 179-188
31. So A, Thorens B. Uric acid transport and disease. The Journal of clinical investigation 2010; 120 (6): 1791-1799
32. Bach MH, Simkin PA. Uricosuric drugs: the once and future therapy for hyperuricemia? Current opinion in rheumatology 2014; 26 (2): 169-175
33. Endou H, Anzai N. Urate transport across the apical membrane of renal proximal tubules. Nucleosides, Nucleotides, and Nucleic Acids 2008; 27 (6-7): 578-584
34. Richette P, Garay R. Novel drug discovery strategies for gout. Expert opinion on drug discovery 2013; 8 (2): 183-189
35. Torralba KD, Jesus E, Rachabattula S. The interplay between diet, urate transporters and the risk for gout and hyperuricemia: current and future directions. International journal of rheumatic diseases 2012; 15 (6): 499-506
36. Villegas R et al. Purine-rich foods, protein intake, and the prevalence of hyperuricemia: the Shanghai Men’s Health Study. Nutrition, Metabolism and Cardiovascular Diseases 2012; 22 (5): 409-416
37. Кадыров ЗА, Истратов ВГ, Сулейманов СИ. Некоторые вопросы этиологии и патогенеза мочекаменной болезни. Урология 2006; 5: 98-102 [Kadyrov ZA, Istratov VG, Sulejmanov SI. Nekotorye voprosy ehtiologii i patogeneza mochekamennoj bolezni. Urologiya 2006; 5: 98-102]
38. Martillo MA, Nazzal L, Crittenden DB. The crystallization of monosodium urate. Current rheumatology reports 2014; 16 (2): 1-8
39. Menon M, Resnick MI. Urinary lithiasis: etiology, diagnosis, and medical management. In: Walsh PC, ed. Campbell’s Urology, 8th ed. Saunders, Philadelphia. 2002; 3229-3305
40. Sakhaee K. Recent advances in the pathophysiology of nephrolithiasis. Kidney international 2009; 75 (6): 585-595
41. Вандер А. Физиология почек. Под ред. Ю.В.Наточина (Пер с англ. Г.А. Лаписа), Питер, СПб., 2000. 256 c. (Renal physiology. Ed. Yu.V.Natochin (Translated from English G.A.Lapis). St Petersburg: Piter, 2000. 256. [Vander A. Fiziologiya pochek. Pod red. YU.V.Natochina (Per s angl. G.A. Lapisa), Piter, SPb., 2000. 256 c. (Renal physiology. Ed. Yu.V.Natochin (Translated from English G.A.Lapis). St Petersburg: Piter, 2000. 256.]
42. Kamel KS, Cheema-Dhadli S, Halperin ML. Studies on the pathophysiology of the low urine pH in patients with uric acid stones. Kidney international 2002; 61 (3): 988-994
43. Sakhaee K et al. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney int 2002; 62(3): 971-979
44. Minkowski O. Untersuchungen zur Physiologie und Pathologie der Harnsäure bei Säugethieren. Archiv für experimentelle Pathologie und Pharmakologie 1898; 41 (6): 375-420
45. Bendich A et al. The direct oxidation of adenine in vivo. Journal of Biological Chemistry 1950; 183 (1): 267-277
46. Simmonds HA, Van Acker KJ. Adenine phosphoribosyltransferase deficiency: 2, 8-dihydroxyadenine lithiasis. Metabolic basis of inherited disease Edited by John B. Stanbury et al. 1983
47. Yokozawa T et al. Adenine-induced hyperuricemia and renal damage in rats. Journal of the agricultural chemical society of japan 1982; 56 (8): 655-663
48. Yokozawa T et al. Animal model of adenine-induced chronic renal failure in rats. Nephron 1986; 44 (3): 230-234
49. Yokozawa T et al. Influence of dietary purine on the level of uric acid in the serum and urine. J Jpn Soc Food Nutr 1981; 34: 35-41
50. Yokozawa T et al. Metabolic effects of dietary adenine in rats Journal of the Agricultural Chemical Society of Japan 1981
51. Yokozawa T et al. Metabolic effects of dietary purine and pyrimidine bases in rats. Agricultural and biological chemistry 1983; 47 (6): 1297-1304
52. Yokozawa T, Oura H, Koizumi F 2, 8-Dihydroxyadenine urolithiasis induced by dietary adenine in rats. Nihon Jinzo Gakkai shi 1985; 27 (3): 371-378
53. Yokozawa T, Zheng PD, Oura H. Biochemical features induced by adenine feeding in rats. Polyuria, electrolyte disorders, and 2, 8-dihydroxyadenine deposits. Journal of nutritional science and vitaminology 1984; 30 (3): 245-254
54. Diwan V et al. Adenine-induced chronic kidney and cardiovascular damage in rats. Journal of pharmacological and toxicological methods 2013; 68 (2): 197-207
55. Adachi S, Yoshizawa F, Yagasaki K. Assay systems for screening food and natural substances that have anti-hyperuricemic activity: uric acid production in cultured hepatocytes and purine bodies-induced hyperuricemic model mice. Cytotechnology 2016; 1-8
56. Epstein FH, Pigeon G. Experimental urate nephropathy: studies of the distribution of urate in renal tissue. Nephron 1964; 1 (3): 144-157
57. Stavric B, Johnson WJ, Grice HC. Uric Acid Nephropathy An Experimental Model. Experimental Biology and Medicine 1969; 130 (2): 512-516
58. Stavric B et al. Uric acid kidney stones induced in rats by oxonic acid, a uricase inhibitor. Investigative urology 1973; 11 (1): 3
59. Waisman J et al. Acute hyperuricemic nephropathy in rats. An electron microscopic study. The American journal of pathology 1975; 81 (2): 367
60. Hoffstein S, Weissmann G. Mechanisms of lysosomal enzyme release from leukocytes. Arthritis & Rheumatism 1975; 18 (2): 153-165
61. Schumacher HR, Phelps P, Agudelo CA. Urate crystal induced inflammation in dog joints: sequence of synovial changes. The Journal of rheumatology 1974; 1 (1): 102
62. Schumacher HR, Phelps P. Sequential changes in human polymorphonuclear leukocytes after urate crystal phagocytosis. An electron microscopic study. Arthritis & Rheumatism 1971; 14 (4): 513-526
63. Kim YG et al. Involvement of macrophage migration inhibitory factor (MIF) in experimental uric acid nephropathy. Molecular Medicine 2000; 6 (10): 837
64. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. New England Journal of Medicine 2008; 359 (17): 1811-1821
65. Mazzali M et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38 (5): 1101-1106
66. Mazzali M et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. American Journal of Physiology-Renal Physiology 2002; 282 (6): F991-F997
67. Wang R et al. Siwu decoction attenuates oxonate-induced hyperuricemia and kidney inflammation in mice. Chinese Journal of Natural Medicines 2016; 14 (7): 499-507
68. Wu X et al. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proceedings of the National Academy of Sciences 1994; 91 (2): 742-746
69. Халфина ТН, Максудова АН, Абдракипов РЗ. Современный взгляд на патогенетические механизмы гиперурикемии. Практическая медицина 2012; 8 (64): 66-67 [Halfina TN, Maksudova AN, Abdrakipov RZ. Sovremennyj vzglyad na patogeneticheskie mekhanizmy giperurikemii. Prakticheskaya medicina 2012; 8 (64): 66-67]
70. Martín NE, Nieto VG. Hypouricemia and tubular transport of uric acid. Nefrologia 2011; 31 (1): 44-50
71. Berliner RW et al. The renal mechanism for urate excretion in man. Journal of Clinical Investigation 1950; 29 (4): 396
72. Gutman AB, Yu TF. A three-component system for regulation of renal excretion of uric acid in man. Transactions of the Association of American Physicians 1961; 74: 353
73. Levinson DJ, Sorensen LB. Renal handling of uric acid in normal and gouty subject: evidence for a 4-component system. Annals of the rheumatic diseases 1980; 39 (2): 173-179
74. Anzai N et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. Journal of Biological Chemistry 2008; 283 (40): 26834-26838
75. Bibert S et al. Mouse GLUT9: evidences for a urate uniporter. American Journal of Physiology-Renal Physiology 2009; 297 (3): F612-F619
76. Preitner F et al. Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proceedings of the National Academy of Sciences 2009; 106 (36): 15501-15506
77. Preitner F et al. Urate-induced acute renal failure and chronic inflammation in liver-specific Glut9 knockout mice. American Journal of Physiology-Renal Physiology 2013; 305 (5): F786-F795
78. Feig DI et al. Serum uric acid: a risk factor and a target for treatment? Journal of the American Society of Nephrology 2006; 17 (4): S69-S73
Review
For citations:
Perfilev V.Yu., Zverev Ya.F., Zharikov A.Yu. CONDITIONS OF URATE NEPHROLITHIASIS AND APPROACHES TO ITS MODELING. Nephrology (Saint-Petersburg). 2017;21(4):48-54. (In Russ.) https://doi.org/10.24884/1561-6274-2017-21-4-48-54
Views:
1391
Email this article 